SMA 200 spoločnosti Neovacs S.A
Aká je hodnota metriky SMA 200 spoločnosti Neovacs S.A?
Hodnota metriky SMA 200 spoločnosti Neovacs S.A. je €0 +100.00%
Aká je definícia metriky SMA 200?
SMA 200 (Simple Moving Average 200) je priemerná cena akcie za posledných 200 dní vypočítaná ako nevážený priemer z predchádzajúcich 200 záverečných cien.
Simple moving average of 200 days for a stock is an unweighted moving average over the past 200 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 200 spoločností v sektore Health Care sektor na EURONEXT v porovnaní so spoločnosťou Neovacs S.A
Čomu sa venuje spoločnosť Neovacs S.A?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Firmy s metrikou sma 200 podobnou spoločnosti Neovacs S.A
- Hodnota metriky SMA 200 spoločnosti Neovacs S.A je €0 +100.00%
- Hodnota metriky SMA 200 spoločnosti EVmo Inc je $0 +96.08%
- Hodnota metriky SMA 200 spoločnosti Predictive Technology je $0 +26.47%
- Hodnota metriky SMA 200 spoločnosti Kaleido Biosciences Inc je $0 +25.93%
- Hodnota metriky SMA 200 spoločnosti Identillect Technologies je CAD$0 +98.52%
- Hodnota metriky SMA 200 spoločnosti Atlas je $0 +79.84%
- Hodnota metriky SMA 200 spoločnosti Cycliq je AUD$0 +98.35%